A. Daifotis

发表

Incidence of Nonvertebral Fractures in Relation to Time on Treatment and Bone Density in Glucocorticoid-Treated Patients: A Retrospective Approach

T. Schnitzer, J. Kaufman, K. Saag, 2003, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men

O. Johnell, J. Reginster, R. Rizzoli, 2005, Osteoporosis International.

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Jacques P. Brown, T. Schnitzer, P. Delmas, 1998, The New England journal of medicine.

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.

P. Gann, K. Anderson, Kenneth Liu, 2007, Journal of the National Cancer Institute.

Weekly administration of alendronate: rationale and plan for clinical assessment.

R. Rizzoli, J. Orloff, S. Prahalada, 2000, Clinical therapeutics.

Effects of Alendronate on Bone Quality and Remodeling in Glucocorticoid‐Induced Osteoporosis: A Histomorphometric Analysis of Transiliac Biopsies

M. Malice, P. Meunier, P. Chavassieux, 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.

P. Sambrook, J. Rodriguez-Portales, G. Fuleihan, 2000, The Journal of clinical endocrinology and metabolism.

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

J. Eisman, M. McClung, P. Ravn, 1998, Annals of Internal Medicine.

Anti-CD3 clinical trials in type 1 diabetes mellitus.

K. Herold, L. Chatenoud, S. Koenig, 2013, Clinical immunology.

Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates

K. Lasseter, A. Denker, A. Daifotis, 2005, Clinical drug investigation.

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study

H. Quan, T. Musliner, B. Sahba, 2002, American Journal of Gastroenterology.

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.

H. Quan, T. Musliner, B. Sahba, 2002 .

Procede d'inhibition de resorption osseuse

A. Santora, A. Daifotis, A. Yates, 1998 .

Methode zur Inhibierung der Knochenresorption

A. Daifotis, A. Yates, I. A. C. Santora, 1998 .

The clinical tolerability profile of alendronate.

N. Watts, A. Daifotis, D. Freedholm, 1999, International journal of clinical practice. Supplement.

Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.

P. Delmas, U. Liberman, S. Goemaere, 2003, Arthritis and rheumatism.

Stretch-induced parathyroid hormone-related peptide gene expression in the rat uterus.

A. Broadus, E. C. Weir, A. Daifotis, 1992, The Journal of biological chemistry.

Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development.

J. Wysolmerski, A. Broadus, W. Philbrick, 1995, Development.

Intrauterine occupancy controls expression of the parathyroid hormone-related peptide gene in preterm rat myometrium.

A. Broadus, R. Garfield, M. Brines, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Immune intervention for type 1 diabetes, 2012-2013.

W. Hagopian, K. Herold, J. Skyler, 2014, Diabetes technology & therapeutics.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

W. Hagopian, S. Pillemer, S. Aronoff, 2011, The Lancet.

Esophagitis associated with the use of alendronate.

Kenneth K Wang, W. P. Stephenson, K. Wang, 1996, The New England journal of medicine.

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

Jacques P. Brown, T. Schnitzer, J. Block, 2001, Arthritis and rheumatism.

Relative overexpression of the parathyroid hormone-related protein gene in human leiomyomas.

E. C. Weir, W. Burtis, R. Nowak, 1994, The Journal of clinical endocrinology and metabolism.

Treatment of Male Osteoporosis: Recent Advances with Alendronate

E. Orwoll, A. Lombardi, J. Ringe, 2002, Osteoporosis International.

Therapeutic Equivalence of Alendronate 35 Milligrams Once Weekly and 5 Milligrams Daily in the Prevention of Postmenopausal Osteoporosis

J. Orloff, A. Santora, M. Luckey, 2003, Obstetrics and gynecology.

Weekly Oral Alendronic Acid in Male Osteoporosis

T. Schnitzer, E. Orwoll, P. Miller, 2004, Clinical drug investigation.

Differential Effects of Alendronate and Estrogen on the Rate of Bone Loss After Discontinuation of Treatment: P-80.

S. Greenspan, A. Mulloy, S. Weiss, 1999 .

Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

Jacques P. Brown, T. Schnitzer, P. Delmas, 1998 .